Cyclacel Pharmaceuticals

At an extraordinary general meeting, Cyclacel shareholders approved the issuance of common shares to Fitters Parent and a potential issuance of more than 20% of outstanding shares to comply with Nasdaq Rule 5635(a). They also approved an amendment to the bylaws to change the company’s name to Bio Green Med Solution, Inc. The company filed audited quarterly financial statements, changed its auditor to SFAI Malaysia PLT, and reappointed five directors for an additional three years. » Plus sur de.investing.com

Shares of Cyclacel Pharmaceuticals fell 14% after surging 270% the previous day, with the company stating it sees no material changes in its operational or financial situation. Cyclacel emphasized that the recent price fluctuations are not due to fundamental developments. The only recent company announcement concerns an amendment to a conversion agreement, which is unrelated to the volatility. » Plus sur de.investing.com

Shares of Cyclacel Pharmaceuticals rose by 50% after the company announced an amended acquisition agreement with FITTERS Diversified Berhad. Cyclacel will acquire all shares of FITTERS subsidiary Fitters Sdn. Bhd. and, in return, will pay FITTERS in shares and a cash component. The transaction, which could expand Cyclacel's business beyond its current pharmaceutical focus, is still subject to shareholder approval. » Plus sur de.investing.com

At its 2025 annual meeting, Cyclacel Pharmaceuticals re-elected all five directors for another three years and approved an increase to its equity incentive plan. Shareholders overwhelmingly supported both measures as well as executive compensation. The company reports a strong short-term liquidity position and, according to analysts, the stock may be potentially undervalued. » Plus sur de.investing.com